Perpetual Medicines
 China
                                                 -                                                 Shanghai
                                                                                                                                    
                                                                                                China
                                                 -                                                 Shanghai
                                                                                            
                                                                                    - 01/12/2023
- Seed
- $8,000,000
About Perpetual Medicines
Perpetual Medicines is a fully integrated computational peptide therapeutics company that aims to build the next-generation peptide drug discovery engine. Perpetual Medicines’ platform will combine leading-edge methods in computational physics including MD simulation, FEP, and quantum chemistry with next-generation AI technologies to predict numerous peptide properties with supreme accuracy. We will also couple this “dry” platform with large-scale synthetic laboratory using state-of-the-art biophysical and chemistry methods for high-throughput peptide synthesis & experimentation. Our vision is to disrupt the enormous 40bn-a-year peptide drug market by heralding in a new renaissance in peptide discovery, design & development.
- Industry Biotechnology Research
- Website https://perpetualmeds.com/index
- LinkedIn https://www.linkedin.com/company/perpetual-medicines/about/
Related People
Kerry BlanchardCo Founder
 China -
                                                         Jing'an District, Shanghai
                                                    
                                                                                                                China -
                                                         Jing'an District, Shanghai
                                                    
                                                Drug discovery and development, cell cycle regulation and control, biology of hypoxia, epigenetics, cancer genetics, translational science
 Syntracts |  $5,300,000  | (Oct 24, 2025)
                                Syntracts |  $5,300,000  | (Oct 24, 2025) 
                             GradBridge |  $20,000,000  | (Oct 24, 2025)
                                GradBridge |  $20,000,000  | (Oct 24, 2025) 
                             Sumble |  $38,500,000  | (Oct 24, 2025)
                                Sumble |  $38,500,000  | (Oct 24, 2025) 
                                     
                                     
                                     
                                     
                                     
                                     
                                     
                                     
                                     
                                             
                                                 
                                                     
                                                 
                                                 
                                                 
                                                 
                                                 
                                                 
                                                     
                                                 
                                                     
                                                 
                                                     
                                                 CipherOwl |  $15,000,000  | (Oct 24, 2025)
                                                                        
                                CipherOwl |  $15,000,000  | (Oct 24, 2025) Sizable Energy |  $8,000,000  | (Oct 24, 2025)
                                                                        
                                Sizable Energy |  $8,000,000  | (Oct 24, 2025) 
                             Elevara Medicines |  $70,000,000  | (Oct 24, 2025)
                                                                        
                                Elevara Medicines |  $70,000,000  | (Oct 24, 2025) Vermeer |  $10,000,000  | (Oct 24, 2025)
                                                                        
                                Vermeer |  $10,000,000  | (Oct 24, 2025) GammaTime |  $14,000,000  | (Oct 24, 2025)
                                                                        
                                GammaTime |  $14,000,000  | (Oct 24, 2025) Cybrid |  $10,000,000  | (Oct 24, 2025)
                                                                        
                                Cybrid |  $10,000,000  | (Oct 24, 2025) 
                             Apriority Financial, Inc. |  $2,300,000  | (Oct 24, 2025)
                                                                        
                                Apriority Financial, Inc. |  $2,300,000  | (Oct 24, 2025) OneAM |  $4,700,000  | (Oct 24, 2025)
                                                                        
                                OneAM |  $4,700,000  | (Oct 24, 2025) 🌱 Rightcharge |  $2,131,920  | (Oct 24, 2025)
                                                                        
                                🌱 Rightcharge |  $2,131,920  | (Oct 24, 2025) Tensormesh |  $4,500,000  | (Oct 24, 2025)
                                                                        
                                Tensormesh |  $4,500,000  | (Oct 24, 2025)